HUP0400475A2 - Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0400475A2 HUP0400475A2 HU0400475A HUP0400475A HUP0400475A2 HU P0400475 A2 HUP0400475 A2 HU P0400475A2 HU 0400475 A HU0400475 A HU 0400475A HU P0400475 A HUP0400475 A HU P0400475A HU P0400475 A2 HUP0400475 A2 HU P0400475A2
- Authority
- HU
- Hungary
- Prior art keywords
- hmg
- receptor antagonist
- pharmaceutical compositions
- compositions containing
- compounds selected
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 2
- 229940123934 Reductase inhibitor Drugs 0.000 title abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgya az alábbiak közül legalább két gyógyhatású anyagottartalmazó készítmény: (i) egy AT1 receptor antagonista vagygyógyászatilag elfogadható adott esetben egy diuretikummal kombinálva,(ii) egy HMG-CO-A reduktáz inhibitor vagy gyógyászatilag elfogadhatósója, vagy (iii) egy ACE inhibitor vagy gyógyászatilag elfogadhatósója, és ennek alkalmazása meghatározott betegségek és állapotokmegelőzésére, előrehaladásának késleltetésére és kezelésére. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19674300P | 2000-04-12 | 2000-04-12 | |
PCT/EP2001/004115 WO2001076573A2 (en) | 2000-04-12 | 2001-04-10 | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400475A2 true HUP0400475A2 (hu) | 2004-06-28 |
HUP0400475A3 HUP0400475A3 (en) | 2006-02-28 |
Family
ID=22726659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400475A HUP0400475A3 (en) | 2000-04-12 | 2001-04-10 | Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040023840A1 (hu) |
EP (1) | EP1326604A2 (hu) |
JP (1) | JP2003530342A (hu) |
KR (1) | KR20020089433A (hu) |
CN (2) | CN1651087A (hu) |
AR (1) | AR032152A1 (hu) |
AU (1) | AU2001258323A1 (hu) |
BR (1) | BR0109966A (hu) |
CA (1) | CA2405793A1 (hu) |
CZ (1) | CZ20023381A3 (hu) |
HU (1) | HUP0400475A3 (hu) |
IL (1) | IL152079A0 (hu) |
MX (1) | MXPA02010090A (hu) |
NO (1) | NO20024921L (hu) |
PE (1) | PE20020229A1 (hu) |
PL (1) | PL365696A1 (hu) |
RU (1) | RU2298418C2 (hu) |
SK (1) | SK14642002A3 (hu) |
WO (1) | WO2001076573A2 (hu) |
ZA (1) | ZA200208203B (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
WO2001097805A2 (en) * | 2000-06-22 | 2001-12-27 | Novartis Ag | Solid valsartan pharmaceutical compositions |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
JP4235000B2 (ja) * | 2001-04-19 | 2009-03-04 | 興和株式会社 | 糸球体疾患治療剤 |
JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CN100438911C (zh) * | 2002-12-27 | 2008-12-03 | 武田药品工业株式会社 | 体重增加抑制剂 |
BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
MXPA05007559A (es) * | 2003-01-16 | 2005-09-21 | Boehringer Ingelheim Int | Combinacion farmaceutica para la prevencion o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales. |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
WO2004096278A1 (ja) * | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | アディポネクチン産生増強剤 |
US7772272B2 (en) | 2003-04-28 | 2010-08-10 | Daiichi Sankyo Company, Limited | Method for enhancing glucose uptake into warm-blooded animal adipocytes |
RS20060018A (en) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
AU2008201290B2 (en) * | 2003-09-26 | 2010-12-09 | Astrazeneca Uk Limited | Therapeutic treatment |
MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
RU2006125512A (ru) * | 2003-12-16 | 2008-01-27 | Новартис АГ (CH) | Применение статинов для лечения метаболического синдрома |
EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
WO2006046528A1 (ja) * | 2004-10-29 | 2006-05-04 | Kowa Co., Ltd. | 糸球体疾患治療剤 |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
JP5101306B2 (ja) * | 2006-01-31 | 2012-12-19 | 興和株式会社 | 糖尿病治療剤 |
FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
RU2505297C1 (ru) * | 2012-11-21 | 2014-01-27 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Средство для медикаментозной коррекции нарушений нитроксидергической системы |
WO2014186269A1 (en) * | 2013-05-13 | 2014-11-20 | Macro Plastics, Inc. | Shipping container and safety catch therefor |
BR102013028883A2 (pt) * | 2013-11-08 | 2015-10-06 | Hypermarcas S A | forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica |
MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
CA2214143A1 (en) * | 1995-04-07 | 1996-10-10 | Marc De Gasparo | Combination compositions containing benazepril or benazeprilat and valsartan |
WO1997002032A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
PT889880E (pt) * | 1996-03-29 | 2003-09-30 | Smithkline Beecham Corp | Di-hidrato de eprosartano e um processo para a sua producao e formulacao |
HU225415B1 (en) * | 1996-07-15 | 2006-11-28 | Sankyo Co | Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma |
-
2001
- 2001-04-10 KR KR1020027013336A patent/KR20020089433A/ko not_active Application Discontinuation
- 2001-04-10 EP EP01931583A patent/EP1326604A2/en not_active Withdrawn
- 2001-04-10 SK SK1464-2002A patent/SK14642002A3/sk unknown
- 2001-04-10 CZ CZ20023381A patent/CZ20023381A3/cs unknown
- 2001-04-10 CN CNA2004101012182A patent/CN1651087A/zh active Pending
- 2001-04-10 PL PL01365696A patent/PL365696A1/xx not_active Application Discontinuation
- 2001-04-10 WO PCT/EP2001/004115 patent/WO2001076573A2/en active Application Filing
- 2001-04-10 US US10/257,559 patent/US20040023840A1/en not_active Abandoned
- 2001-04-10 CN CN01807919A patent/CN1440283A/zh active Pending
- 2001-04-10 BR BR0109966-3A patent/BR0109966A/pt not_active IP Right Cessation
- 2001-04-10 AR ARP010101697A patent/AR032152A1/es not_active Application Discontinuation
- 2001-04-10 HU HU0400475A patent/HUP0400475A3/hu unknown
- 2001-04-10 RU RU2002129558/15A patent/RU2298418C2/ru not_active IP Right Cessation
- 2001-04-10 IL IL15207901A patent/IL152079A0/xx unknown
- 2001-04-10 CA CA002405793A patent/CA2405793A1/en not_active Abandoned
- 2001-04-10 AU AU2001258323A patent/AU2001258323A1/en not_active Abandoned
- 2001-04-10 PE PE2001000327A patent/PE20020229A1/es not_active Application Discontinuation
- 2001-04-10 MX MXPA02010090A patent/MXPA02010090A/es active IP Right Grant
- 2001-04-10 JP JP2001574091A patent/JP2003530342A/ja active Pending
-
2002
- 2002-10-11 ZA ZA200208203A patent/ZA200208203B/en unknown
- 2002-10-11 NO NO20024921A patent/NO20024921L/no not_active Application Discontinuation
-
2006
- 2006-10-31 US US11/590,215 patent/US20070105894A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CZ20023381A3 (cs) | 2003-02-12 |
EP1326604A2 (en) | 2003-07-16 |
CA2405793A1 (en) | 2001-10-18 |
AU2001258323A1 (en) | 2001-10-23 |
PE20020229A1 (es) | 2002-04-11 |
HUP0400475A3 (en) | 2006-02-28 |
SK14642002A3 (sk) | 2003-05-02 |
BR0109966A (pt) | 2003-08-05 |
AR032152A1 (es) | 2003-10-29 |
US20070105894A1 (en) | 2007-05-10 |
CN1440283A (zh) | 2003-09-03 |
RU2298418C2 (ru) | 2007-05-10 |
NO20024921D0 (no) | 2002-10-11 |
US20040023840A1 (en) | 2004-02-05 |
NO20024921L (no) | 2002-11-07 |
KR20020089433A (ko) | 2002-11-29 |
CN1651087A (zh) | 2005-08-10 |
WO2001076573A3 (en) | 2003-04-17 |
ZA200208203B (en) | 2003-11-07 |
WO2001076573A2 (en) | 2001-10-18 |
IL152079A0 (en) | 2003-05-29 |
JP2003530342A (ja) | 2003-10-14 |
PL365696A1 (en) | 2005-01-10 |
MXPA02010090A (es) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400475A2 (hu) | Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0301841A2 (hu) | Kardiovaszkuláris betegségek gyógyítására alkalmas renin inhibitort tartalmazó szinergetikus hatású kombinációs készítmények és alkalmazásuk | |
HUP0401191A2 (hu) | Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények | |
HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
WO2001076574A3 (en) | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists | |
HUP0204163A2 (hu) | Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására | |
TR200001942T2 (tr) | Opioid agonist/antagonist kombinasyonlar | |
NO20011502D0 (no) | Fentanylsammensetning for behandling av akutt smerte | |
GB2419529A (en) | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome | |
HUP0301244A2 (hu) | Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására | |
HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
HUP0202862A2 (hu) | A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény | |
DK0680326T3 (da) | Farmaceutisk formulering af nikotinafhængighed. | |
HUP0301892A2 (hu) | Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk | |
MXPA06000705A (es) | Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos. | |
BRPI0414558A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide | |
HUP0400850A2 (hu) | Orálisan adagolható gyógyászati készítmények | |
EE05054B1 (et) | 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis | |
HUP0400553A2 (hu) | Gyógyászati készítmények | |
HUP0203241A2 (hu) | Heterotrimer G-fehérje jelátvitel inhibitor és egy rákellenes hatóanyag-kombináció alkalmazása rákbetegség gyógyítására | |
HUP0204511A2 (en) | Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas | |
WO2005004915A3 (en) | Compositions comprising meloxicam | |
BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
TR200200913T2 (tr) | Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. | |
EP1849468A3 (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |